Preclinical Cancer Articles & Analysis: Older
7 articles found
These innovative methods enable the identification and generation of highly specific antibodies that can deftly navigate the complex tumor microenvironment of bladder cancer. By harnessing a deep understanding of immunology and molecular biology, Alfa Cytology strives to supply more possibilities for preclinical therapeutic regimens. In addition to therapeutic ...
CD BioSciences has launched new services on anti-centrosome antibody development to assist cancer preclinical research. It is committed to providing full packages from antigen synthesis to antibody generation and manufacturing. ...
Alfa Cytology has announced tumor models customization service for pancreatic cancer research. Alfa Cytology, a biotech company specializing in cancer research, has recently unveiled the service on pancreatic cancer tumor model customization to dig into the generation and development of pancreatic cancer and correspondingly ...
Alfa Cytology has announced its small molecule drug development to advance preclinical cancer research. Alfa Cytology, a comprehensive biotech company specializing in cancer research, has recently announced the cancer small molecule drug development services. ...
Further complexity arises as cancer cells also express the adenosine A1 receptor (ADORA1) and A3 receptor (ADORA3). ...
Enfortumab vedotin-ejfv (PADCEV®) is a first-in-class antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein highly expressed in bladder cancer. Preclinical data suggest that the anticancer activity of Enfortumab Vedotin is attributed to its binding to cells expressing Nectin-4, followed by internalization and release of the anti-tumor ...
However, in a new study, researchers from the University of Michigan Roger Cancer Center and the University of Pennsylvania found that hyaluronic acid also acts as a food for cancer cells. The results provide new insights into how pancreatic cancer cells grow and point to new possibilities for the treatment of this cancer. ...